Introduction
E1-deleted recombinant adenoviruses efficiently deliver genes to a wide spectrum of nondividing cells in vivo. 1 Gene expression, however, is transient generally lasting less than 2-3 weeks and is associated with substantial inflammation at the site of transgene expression. [2] [3] [4] The observation that transgene expression is prolonged in immune-deficient mice suggested that host immune responses may limit the performance of recombinant adenoviruses as gene transfer vehicles. [2] [3] [4] Previous studies indicated that instillation of E1-deleted adenovirus into mouse liver and lung causes activation of MHC class I-restricted, CD8
+ cytotoxic T lymphocytes, that are responsible for the destruction of virus-infected cells. [4] [5] [6] Furthermore, adenoviral vectors stimulate B cells to secrete virus neutralizing antibodies which block readministration of vector. 7, 8 Both CTL and B cell effector responses require activation of CD4 + T cells of the T H1 and T H2 subsets, respectively.
9,10 CD4 + T cells are activated to exogenous antigens such as viral capsid proteins, which are presented by MHC class II. The central role of CD4 + T cells in the activation of both arms of the immune response suggests that a transient blockade of CD4
+ T cells at the time of virus administration might prevent the activation of humoral and cellular immune responses to adenoviral vectors, thus causing prolonged transgene expression and efficient readministration without chronic immune suppression.
Activation of naïve T cells requires a number of signaling events in addition to that resulting from engagement of the T cell receptor with the peptide-MHC complex.
11 CD40 ligand (CD40L) is transiently up-regulated on the T cell subsequently binding to CD40 on APCs. 12 This signals the APC to increase B7 which binds to CD28 on the T cell, resulting in cytokine secretion and full T cell activation. 13 Blockade of either CD40L-CD40 or CD28-B7 interactions at the time of virus administration might suppress the activation of the immune response and lead to stable gene expression. In models of allograft rejection, however, these signaling pathways appear to be uncoupled. 14 We evaluated the impact of a soluble form of human CTLA4Ig (huCTLA4Ig, a chimeric protein of human immunoglobulin C␥2a fused to human CTLA4), on the cellular and humoral immune responses to adenoviral vectors in liver and lung. Preliminary studies demonstrating the value of this approach were presented by Kay et al. 15 Our data show that CTLA4Ig reduces activation of CD4 + and CD8 + T cells, as well as of antibody formation. Transgene expression was prolonged and at least upon targeting the airways, readministration of adenoviral vectors was possible.
Results

HuCTLA4Ig stabilizes gene expression in liver
To study the impact of huCTLA4Ig on cellular and humoral immune responses to E1-deleted adenoviral vectors in liver and lung, C57BL/6 mice were injected with a lacZ-expressing adenoviral vector on day 0 and ALPexpressing virus on days 28 or 56. Similar results were obtained when the order of vectors was reversed. For lung-directed gene transfer, virus was instilled into the trachea while intravenous injections of virus were used to effect gene transfer to liver. A blockade of the costimulatory pathway mediated by CD28 and B7.1/B7.2 at the time of viral infection was attempted by administering huCTLA4Ig on days 0, 1, 2, 3 and 4. Lung or liver tissues were harvested on days 3, 14 and 28 to evaluate stability of transgene expression, as well as virus-induced inflammatory responses, while lymphocytes were isolated on day 10 from regional lymph nodes (lung) or spleen (liver) to determine vector-specific T cell activation. Serum was taken before the second virus administration (days 28 or 56) to look for the formation of neutralizing antibodies and tissues harvested for analysis of reporter gene expression 3 days later (days 31 and 59). In Figures 1 and 3 for liver and lung studies, while the accompanying morphometrical data are summarized in Figure 2 and Table  1 . C57BL/6 mice were used in this study because of the vibrant and well characterized immune responses to E1-deleted lacZ viruses that have been described in this strain. 5, 6 Similar responses to these vectors have been observed in BalbC and C3H mice (data not shown).
High-level transgene expression was achieved in livers of C57BL/6 mice 3 days after administration of lacZ vector (Figure 1a and e) . Without immune suppression, reporter gene expression diminished to undetectable levels by day 14 (Figure 1b) , whereas five administrations of huCTLA4Ig (daily injection from day 0 to day 4) were sufficient to stabilize transgene expression for 28 days (Figure 1g ). Morphometric analysis of lacZ-positive hepatocytes demonstrates stable reporter gene expression in huCTLA4Ig treated animals up to day 28 ( Figure 2) .
Treatment with huCTLA4Ig has less of an impact on the stabilization of transgene expression when evaluated in the lung model of adenovirus-mediated gene transfer. Intratracheal instillation of E1-deleted virus resulted in efficient gene transfer in more than 75% of airways at day 3 ( Figure 3a and f), which in untreated animals diminished to undetectable levels by day 14 ( Figure 3b ). Coadministration of huCTLA4Ig at the time of virus Figure 1 administration prolonged reporter gene expression up to day 14 (Figure 3g ), which then rapidly diminished by day 28 (Figure 3h) . Table 1 provides a quantitative summary of transgene expression in the lung. Thus, administration of huCTLA4Ig at the time of virus instillation more efficiently prolongs transgene expression in the liver, than in the lung.
Transient blockade of CD28/B7 suppresses activation of CD4 + and CD8 + T cells in liver and lung To investigate the mechanism responsible for huCTLA4Ig-mediated stabilization of transgene expression, we investigated the impact of huCTLA4Ig treatment on the activation of virus-specific CD4 + and CD8 + T lymphocytes. The effect of huCTLA4Ig on the activation of CD4 + T cells was analyzed by measuring cytokine release by T lymphocytes. Lymphocytes were harvested at day 10 after virus instillation from regional lymph nodes (lung) or spleen (liver) and restimulated in vitro with UVinactivated virus. Cytokine activity was tested on the IL-2-and IL-4-dependent cell line, HT-2. Data are presented in Table 2 . The stimulation index is determined by measuring thymidine uptake of HT-2 cells activated with supernatant from lymphocytes which were stimulated Transgene expression presented in Figure 3 (d3, d14 and d28: LacZ, d31: ALP) has been quantified by counting a total of 30 airways from two mice using the following criteria: no transgene expressing epithelial cells (0), transgene expression in 1 to 25% of epithelial cells , and transgene expression in more than 25% of epithelial cells (Ͼ25). The data presented are from untreated animals (control) and animals treated with huCTLA4Ig (huCTLA4Ig). with UV-inactivated virus relative to supernatant from unstimulated lymphocytes. Administration of vector via both routes significantly activated CD4 + T cells, resulting in a stimulation index of 18.9 ± 1.1 in lung and 10.8 ± 1.7 in liver. Coadministration of huCTLA4Ig reduced T cell activation about 50% for both routes of administration.
We next investigated if huCTLA4Ig could also effect the activation of cytotoxic T lymphocytes either directly or through its effect on CD4 + T cells. Virus-specific cytotoxic T lymphocytes were tested in a standard chromium release assay on MHC-compatible target cells previously infected with E1-deleted adenovirus and subsequently loaded with chromium ( Figure 4) . The effector cells were isolated 10 days after virus instillation and restimulated in vitro with adenovirus. As shown previously, high specific lysis was obtained with splenocytes isolated from vector-infected animals. CTL activity was substantially reduced upon treatment with huCTLA4Ig as shown in Figure 4 .
Inflammatory responses are reduced in huCTLA4Ig-treated animals
The impact of huCTLA4Ig treatment on the activation of CD4
+ and CD8 + T cells was further investigated by phenotyping the lymphocytic infiltrate in the target organ ( Figures 5 and 6 ). Frozen sections of liver were stained for the presence of CD4 + and CD8 + T cells, as well as for levels of MHC class I expression on the basolateral surface of hepatocytes. Experiments in lung were restricted to CD4
+ and CD8 + T cell detection because of technical problems with the MHC class I detection. Infection of C57BL/6 mice with E1-deleted adenovirus resulted at day 14 in massive infiltration of the organs with T lymphocytes which, in liver were identified as predominantly CD4
+ T cells (Figure 5a ) with some CD8 + T cells (Figure 5d ). Coadministration of huCTLA4Ig at the time of virus instillation prevented the appearance of lymphocytes (ie CD4 + T cells, Figure 5b and CD8 + T cells, Figure  5e ). Background staining was determined with organ sections from naive animals (Figure 5c and f). The up-regulation of MHC class I expression detected after adenoviral infection on the surface of hepatocytes (Figure 5g) was not influenced by the huCTLA4Ig treatment of the animals ( Figure 5h) ; it was still significantly higher than in uninfected mice (Figure 5i) .
We established criteria to evaluate liver histopathology in order to quantify the inflammatory responses seen after adenoviral infection. These quantitative histopathology data are summarized in Figure 7 . C57BL/6 mice infected with E1-deleted adenovirus showed clear signs of intralobular and portal inflammation, as well as apoptotic figures, which were drastically reduced in huCTLA4Ig treated C57BL/6 mice ( Substantial numbers of CD4 + and CD8 + T cells were present in lung after vector administration (Figure 6a and d, respectively). This vector-induced inflammatory response was entirely inhibited when animals received five huCTLA4Ig injections (Figure 6b and e) . The specificity of the staining was demonstrated with lung sections from naive animals (Figure 6c and f) .
Formation of neutralizing antibodies is efficiently blocked in lung
In addition to cellular immune responses, humoral immune responses to virus are a fundamental problem in animals infected with E1-deleted adenovirus. It has been demonstrated in various studies that the formation of
Figure 4 Activation of adenovirus-specific cytotoxic T lymphocytes in mice treated with huCTLA4Ig. C56BL/6 mice were infected with E1-deleted adenovirus and subsequently treated with huCTLA4Ig (open diamonds). Control animals did not undergo huCTLA4Ig treatment (open squares). Data are representative of two separate experiments. Mediastinal lymph nodes (lung) or spleens (liver) were isolated 10 days after infection and cells restimulated in vitro for 5 days. Specific lysis was determined on mock-infected (left panels) or lacZ virus infected (right panels) C57SV cells in a 6-h 51
Cr release assay. Percentage specific lysis is expressed as a function of different effector:target cell ratios.
neutralizing antibodies blocks readministration of virus. To study the impact of huCTLA4Ig on the formation of neutralizing antibodies, sera and bronchoalveolar lavage fluids (BAL) were harvested 28 days after the first virus instillation and tested for vector-specific antibodies. A second virus, expressing the ALP transgene, was subsequently administered to evaluate the impact of huCTLA4Ig on vector readministration. As shown in Table 3 , virus instillation into the trachea resulted in neutralizing antibody titers of 1:1280 in serum and 1:640 in BAL, while i.v. infusion of vector led to a neutralizing antibody titer of 1:1280. huCTLA4Ig treatment inhibited formation of neutralizing antibodies to levels below detectability upon intratracheal administration of the adenoviral recombinant (Table 3 ). These data are in agreement with additional results that showed successful readministration of virus 4 or 8 weeks later (Figure 3i and j, respectively). In contrast, neutralizing antibody formation could not be blocked upon intravenous inoculation of the recombinant (Table 3 ). This route of administration did not allow successful readministration of an adenoviral recombinant in huCTLA4Ig treated mice (Figure 1h) . A naive mouse injected on day 28 with the second adenovirus served as a positive control for maximal gene transfer (Figure 1i ).
Discussion
Strong vector-specific immune responses follow the administration of E1-deleted adenovirus into mouse liver and lung. Previous studies have shown that the destruction of virus-infected cells is mediated by antigen-specific cytotoxic T lymphocytes. [4] [5] [6] In addition, B cells are activated to adenoviral capsid proteins, leading to the formation of neutralizing antibodies which interfere with successful readministration of the virus.
7-8 CD4 + T cells play a central role in the activation of both arms of the immune response, and their depletion causes stable transgene expression and allows successful readministration of the virus. 9, 10 In order to utilize adenoviral vectors for gene therapy, strategies that abrogate induction of immune responses need to be designed. Transient immune suppression utilizing cyclosporin A or cyclophosphamide. 4, 16, 17 or CD4 + antibodies, 9,18 as well as more selective inhibition of the T H2 subset of the T helper cells by administering the cytokines IL-12 or IFN␥ at the time of virus administration has been shown to prolong transgene expression. 9 Ideal immune-suppressive strategies in the context of gene therapy, however, should be antigen-specific. Global immune suppression using drugs like cyclosporin A or transient antibody-mediated depletion of essential immune effector cells (eg CD4 + T cells) may make patients generally susceptible to infections. These concerns, in addition to the fact that CD4 + T cells are essential for the activation of cellular and humoral immune responses, guided the research of immune blockade towards intervention of CD4 + T cell activation. The first interaction between a CD4 + T cell and an antigenpresenting cell (APC) is the engagement of the T cell receptor on the CD4 + T cell with the antigen bound to the MHC class II molecule on an APC. This interaction is followed by the up-regulation of several accessory molecules with costimulatory function. Indeed, TCR ligation
Figure 5 Immunophenotyping of the liver. Immunohistochemical staining was performed for MHC class I (g, h, i), CD4 + (a, b, c,) and CD8 + T cells (d, e, f) performed on liver sections of animals which had been infected with E1-deleted virus on day 0. Some animals were treated with huCTLA4Ig (b, e, h). Control animals did not receive huCTLA4Ig treatment (a, d, g). The background was determined on liver sections from naive mice (c, f, i). Liver sections taken on day 14 after adenoviral infection were stained for MHC class I expression with mAb to H-2K
b D b (
bottom row) and for the presence of CD4 + (top row) and CD8 + T cells (middle row).
without costimulation can result in functional inactivation or anergy of T helper cells, which make these molecules an ideal target for antigen-specific suppression of CD4 + T cell activation. 19 In T cell-dependent B cell responses, binding of antigen to the TCR leads to the engagement of CD40L on T cells with CD40 on cognate B cells. 12 Ligation of CD40L with CD40 seems to activate a cascade of events involving the interaction of two receptors on the T cell, CD28 and CTLA4 with ligands, B7.1 and B7.2, on the B cell or APC. 12 Previous studies by Yang et al 20 successfully demonstrated the prevention of T cell activation to adenoviral vectors by administering CD40L antibody at the time of virus administration. In addition, CD40L knockout mice showed persistence of transgene expression, as well as the ability to readminister virus when E1-deleted adenovirus was instilled into these animals. 20 Although the engagement of CD40L with CD40 stimulates the interaction of CD28 with B7, it is still not clearly defined if the latter molecules are the downstream effectors of CD40L/CD40 signaling. Moreover, studies on skin and cardiac allografts demonstrated that long-term accept- 
e). Control animals did not receive huCTLA4Ig injections (a, d). Lung tissue harvested on day 14 was histochemically stained for the presence of CD4 + cells (a-c) and CD8 + T cells (d-f) using monoclonal antibodies to CD4
+ and CD8
+ . The background was determined in staining lung tissue from naive animals (c, f). These data are representative of three lung sections each (magnification, × 200).
ance can only be achieved if CD28 and CD40 pathways are blocked simultaneously but not independently which leads to the conclusion that CD28 and CD40 pathways are critical independent regulators of T cell-dependent immune responses. 14, 21 Two cell surface molecules have been identified on T cells, which interact with the B7 family on B cells delivering costimulatory signals after TCR engagement. Blocking studies of CD28 signaling clearly revealed its function as a positive costimulatory molecule, whereas the role of CTLA4 in the regulation of T cell activation has been controversial. 22, 23 A role for CTLA4 in downregulating T cell activation has been proposed from studies on CTLA4 knockout mice which develop lymphoproliferative disorders. 24, 25 Support for this hypothesis has been derived from experiments utilizing anti-CTLA4 antibodies. 23, 26 In contrast, however, suppression of cellmediated immunity could be achieved when CTLA4-Ig was used in different experimental settings. [27] [28] [29] [30] The latter observation is supported by data presented in this study, which demonstrate inhibition of T and B cell activation by an adenoviral recombinant in animals treated with huCTLA4Ig.
In order to study the role of CD28, CTLA4/B7.1 and B7.2 signaling we coadministered huCTLA4Ig (a chimeric protein of human immunoglobulin C␥2a fused to human CTLA4) at the time we instilled an E1-deleted adenovirus into mouse liver and lung and investigated its impact on the activation of cellular and humoral immune responses to the vector. In lung, transient inhibition of CTLA4 with CTLA4Ig blocked B cell effector responses, which resulted in full inhibition of neutralizing antibody formation and therefore high efficiency of vector readministration even by day 56. These data indicate that transient immune suppression is indeed sufficient to allow readministration of virus even at a time when CTLA4Ig is not present. The impact on the persistence of transgene expression, however, was less impressive. In liver, transgene expression was clearly present at day 28, whereas CTLA4Ig treatment did not diminish humoral immune responses.
Although we can currently not explain the differing effects of the drug on the humoral and cellular immune responses in lung versus liver, several animal studies utilizing immunosuppressive drugs or cytokine treatment in the context of viral infection have described similar findings. 9, 15, 17, 20 It is known however, that secretory IgA, which depends on help by Th2 cells, contributes to neutralization of virus in lung, whereas antibodies of other isotypes, such as IgG1 and IgG2a neutralize virus administered systemically. Second, different routes of virus instillation may result in different mechanisms of antigen presentation, which could affect inhibition of B and T cell activation by CTLA4Ig. Yang et al 20 reported in liver studies that the efficiency of vector readministration was more impressive in the CD40L knockout mice than in animals transiently depleted with CD40L mAb, whereas in lung, transient administration of the antibody efficiently 
of H5.010CMVlacZ on day 0 and treated with huCTLA4Ig (gray bars). Control animals did not receive huCTLA4Ig treatment (dotted bars). Three animals each were killed on days 3, 14 and 28, livers fixed and stained with H&E and estimated for characteristics of intralobular inflammation (a), portal inflammation (b), apoptotic (c), as well as mitotic (d) events. The quantitative measures of liver pathology are described in the Materials and methods.
317 blocked the formation of neutralizing antibodies. These data suggest that the threshold for blockade of neutralizing antibody seems to be higher in liver than in lung.
The partial effect obtained with CD40L antibody 20 and cyclophosphamide 17 is probably due to incomplete blockade achieved with the drugs and not redundant pathways. Interpretation of the CTLA4Ig effects are further confounded because it interferes with both activation (ie CD28) and inhibitory (ie CTLA4) pathways. It is also worth mentioning that a human form of the fusion protein (huCTLA4Ig) is used in these studies, which might have lower affinity for its receptor than the murine form. However, in liver studies performed by Kay et al 15 utilizing muCTLA4Ig for immune suppression, readministration of virus was also not possible.
In spite of the fact that transgene expression is only modestly prolonged in the lung, whereas persistence was observed in liver, in vitro studies of lymphocytes clearly demonstrate suppression of T cell activation in liver and lung studies by CTLA4Ig. CTLA4Ig treatment suppressed CTLs and T helper cell activation equally well in both systems; infiltration of CD4 + and CD8 + T cells was diminished in both organs. It can only be speculated that other unknown factors independent of CTLs may contribute to the elimination of reporter gene expression in the lung. The previous demonstration that persistence of transgene expression in lung was dependent on the dose of another immune suppressant, cyclophosphamide, suggests a threshold effect in the blockade of cellular immune responses in this organ. 17 These studies indicate the usefulness of a transient administration of CTLA4Ig at the time of virus instillation in suppressing cellular and humoral immune responses depending on the organ studied. The safety of CTLA4Ig for human application is unknown although it is likely to have a more specific effect on immune function than general immune suppressants, such as cyclophosphamide and cyclosporin A. Moreover, all studies published utilizing CTLA4Ig as an immunosuppressive reagent have demonstrated some level of inhibition of both the cellular and humoral arm of the immune response, [27] [28] [29] making this drug an attractive tool for human application. The data, however, demonstrating only partial blockade of the immune responses, such as neutralizing antibody following intravenous vector delivery, suggest that more potent blockers of these accessory, costimulatory molecules may be required.
Material and methods
Animal studies Female mice (C57BL/6) were purchased at 7-8 weeks of age from Jackson Laboratory (Bar Harbor, ME, USA). On day 0, 5 × 10 8 p.f.u. of the recombinant adenovirus H5.010CMVlacZ (an E1-deleted adenovirus expressing the lacZ gene from the CMV promoter on the sub360 backbone) was instilled into lung via the trachea. For liver studies 1 × 10 9 p.f.u. of the same virus was injected intravenously (i.v.) into C57BL/6 mice. CTLA4Ig (100 g per 100 l), provided by Peter Linsley (Bristol-Myers Squibb, Seattle, WA, USA), was injected i.v. on days 0, 1, 2, 3 and 4. Doubling the dose of CTLA4Ig had no effect while decreasing the dose or number of administrations resulted in partial responses in terms of blockade of T cell activation and prolongation of transgene expression. On day 28 (liver and lung studies) or day 56 (for lung studies only) a second E1-deleted adenovirus was administered (H5.010CBALP) which expresses the alkaline phosphatase gene from the CMV-enhanced ␤-actin promoter in the sub360 backbone. Animals were killed on days 3, 14, 28 and 31 for liver studies and days 3, 14, 28, 31 and 59 for lung studies and tissues were prepared for cryosections, while spleen, bronchial alveolar lavage (BAL) and mediastinal lymph nodes (MLN) were harvested for immunological analyses.
Morphological analyses
For immunohistochemical analyses, lungs were inflated with a 1:1 mixture of PBS/OCT, whereas liver tissues were inflated in OCT. Both tissues were quickly frozen in liquid nitrogen and blocks of tissue were cryosectioned. For alkaline phosphatase staining, frozen sections were fixed in 0.5% glutaraldehyde for 10 min and washed twice in PBS. To inactivate the endogenous alkaline phosphatase, the sections were treated at 65°C for 30 min. Staining was performed for 30 min in 100 mm Tris-HCl (pH 9.5), 100 mm NaCl, 50 mm MgCl 2 containing 0.165 mg BCIP (5-bromo-4-chloro-3-indolyl phosphatase) and 0.33 mg of nitroblue tetrazolium per ml at 37°C. For Xgal (5-bromo-4-chloro-3-indolyl ␤-d-galactopyranoside) staining of tissue, sections were fixed in 0.5% glutaraldehyde for 10 min, washed extensively with PBS containing 1 mm MgCl 2, , and incubated in 1 mg of X-Gal per ml, 5 mm K 3 Fe(CN) 6 , 5 mm K 4 Fe(CN) 6 , and 1 mm MgCl 2 in PBS for 4 h.
CTL assay
The CTL assay was performed as described previously. 31 Briefly, three spleens from virus infected mice were removed, splenocytes stimulated in vitro for 5 days with H5.010CMVlacZ (MOI 0.5) and assayed against 51 Cr labeled target cells, which were previously infected with H5.010CMVlacZ. The CTL assay was performed using different effector:target cell ratios. CTL activity was measured by a 6-h Immunofluorescence Before staining of the lung and liver tissue, sections were fixed in methanol at −20°C for 10 min. Nonspecific binding was blocked in 10% goat serum/PBS for 30 min, after two cycles of air-drying and rehydrating in PBS. For detection of CD8 + or CD4 + T cells, sections were either incubated for 2 h with a rat anti-mouse CD4
+ antibody (anti L3T4, GibcoBRL, 1:100 dilution in 2% goat serum), followed by a 30-min incubation with 5 g of goat antirat immunoglobulin G (IgG)-fluorescein or with a rat anti-mouse CD8 + ␣-fluorescein isothiocyanate G (anti-Ly-2, GibcoBRL, Grand Island, NY, USA; 1:100 dilution in 2% goat serum). Hela cells (70-80% confluent) in 96-well plates. After 1 h of infection, 100 l of DMEM containing 20% FBS was added. The cells were fixed with 0.5% glutaraldehyde and stained for ␤-galactosidase activity (as described in Morphological analyses) 16-18 h later. In the absence of antibody, all of the cells stained blue. The neutralizing antibody titer was determined as the highest dilution that caused staining of 50% of the cells.
